NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
XELSTRYM (dextroamphetamine) by Noven Pharmaceuticals is clinical pharmacology amphetamines are noncatecholamine, sympathomimetic amines with cns stimulant activity. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELSTRYM is a transdermal dextroamphetamine system approved in 2022 for the treatment of ADHD and narcolepsy. It is a CNS stimulant that works by elevating sympathomimetic activity and enhancing dopamine and norepinephrine signaling. The transdermal route offers an alternative to oral amphetamine formulations with potentially improved compliance and consistent drug delivery.
$0.051BPart D
Peak15.3 years to LOEEarly-stage product at peak adoption phase with modest Medicare penetration; small commercial footprint suggests focused team structure and opportunity to scale.
Mechanism of Action
CLINICAL PHARMACOLOGY Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly…
Pharmacologic Class:
Central Nervous System Stimulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
Worked on XELSTRYM at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.